Table 2.
Baseline characteristics.
| Characteristic | All (n = 162) |
SCCHN (n = 144) |
NSCCHN (n = 17) |
|---|---|---|---|
| Median age, years (range) | 68 (38–89) | 68 (38–89) | 71 (39–87) |
| >65, n (%) | 93 (57.4) | 81 (56.3) | 11 (64.7) |
| Sex, n (%) | |||
| Male | 114 (70.4) | 107 (74.3) | 7 (41.2) |
| Female | 48 (29.6) | 37 (25.7) | 10 (58.8) |
| ECOG-PS, n (%) | |||
| 0 | 78 (48.2) | 69 (47.9) | 9 (52.9) |
| 1 | 78 (48.2) | 70 (48.6) | 8 (47.1) |
| 2 | 5 (3.1) | 5 (3.5) | 0 |
| Unknown | 1 (0.6) | 0 | 0 |
| Tumor location, n (%) | |||
| Cervical lymph node | 52 (29.2) | 49 (30.8) | 3 (16.7) |
| Hypopharynx | 24 (13.5) | 24 (15.1) | 0 |
| Oral (excluding tongue) | 20 (11.2) | 19 (12.0) | 1 (5.6) |
| Oropharynx | 18 (10.1) | 18 (11.3) | 0 |
| Larynx | 11 (6.2) | 11 (6.9) | 0 |
| External auditory canal | 10 (5.6) | 10 (6.3) | 0 |
| Maxillary sinus | 6 (3.4) | 6 (3.8) | 0 |
| Nasopharynx | 5 (2.8) | 2 (1.3) | 3 (16.7) |
| Maxilla | 5 (2.8) | 4 (2.5) | 1 (5.7) |
| Parotid gland | 5 (2.8) | 1 (0.6) | 4 (22.2) |
| Orbit | 4 (2.3) | 3 (1.9) | 1 (5.7) |
| Parapharyngeal space | 3 (1.7) | 2 (1.3) | 1 (5.7) |
| Tongue | 3 (1.7) | 3 (1.9) | 0 |
| Brain | 1 (0.6) | NA | NA |
| Others | 11 * (6.2) | 7 ** (4.4) | 4 *** (22.2) |
| TNM classification, n (%) | |||
| T1–2 | 48 (30.3) | 43 (29.9) | 5 (29.4) |
| T3–4 | 72 (45.6) | 63 (43.8) | 9 (52.9) |
| N1–2 | 33 (20.5) | 31 (21.5) | 2 (11.8) |
| N3 | 19 (11.8) | 18 (12.5) | 1 (5.9) |
| Prior systemic therapy, n (%) | 128 (79.0) | 120 (83.3) | 8 (47.1) |
| Prior radiation therapy, n (%) | 151 (93.2) | 136 (94.4) | 14 (82.4) |
|
Median cumulative dose,
Gy (range) |
70 (24–130) | 70 (24–130) | 68 (48–90) |
| Duration from last irradiation | |||
| <6 months, n (%) | 20 (13.3) | 19 (14.0) | 1 (7.1) |
| ≥6 months, n (%) | 128 (84.8) | 114 (83.8) | 13 (92.9) |
| Unknown | 3 (2.0) | 3 (2.2) | 0 |
* Included “neck (detail unspecified)” in two cases, and “nasal cavity”, “ethmoid sinus”, “pterygopalatine fossa”, “mandible”, “buccal area (detail unspecified)”, “eyelid”, “nasolacrimal canal”, “sublingual gland”, and “superior mediastinum” in one case each. ** Included “neck (detail unspecified)” in 2 cases, and “nasal cavity”, “pterygopalatine fossa”, “mandible”, “buccal area (detail unspecified)”, “superior mediastinum” in one case each. *** Included “ethmoid sinus”, “eyelid”, “nasolacrimal canal”, and “sublingual gland” in one case each. Abbreviations: SCCHN, squamous cell carcinoma of the head and neck; NSCCHN, non-squamous cell carcinoma of the head and neck; ECOG-PS, Eastern Cooperative Oncology Group Performance Status.